Prognostic significance of inflammation-related and electrolyte laboratory variables in patients with malignant pleural mesothelioma

Objective Malignant pleural mesothelioma (MPM) is a kind of pleural cancer characterized by low incidence but high invasiveness. There is heterogeneity in survival among patients with MPM. Inflammation-related and electrolyte laboratory variables were previously reported as potential predictors of survival. We evaluated the relationship between overall survival and pre-treatment biomarkers. Materials and methods Patients diagnosed with MPM in Beijing Chaoyang Hospital for more than 10 years were screened for this study. All basic, clinical, radiologic and laboratory variables were collected. The COX univariable and multivariable analysis were used to explore prognostic related risk factors. Results Ninety patients with MPM were included. The median follow-up of all patients was 57 months [interquartile range (IQR): 27–100 months]. The median survival time was 24 months (IQR: 12–52 months). Univariate survival analyses indicated that age, Eastern Cooperative Oncology Group Performance Status, treatment, erythrocyte sedimentation rate, calcium, lymphocyte, hemoglobin, platelet-to-lymphocyte ratio (PLR), and monocyte-to-white blood cell ratio (MWR) were significantly related to survival. Multivariable analysis demonstrated that age [hazard ratio (HR), 2.548; 95% confidence interval (CI) 1.145–5.666; p = 0.022], calcium (HR, 0.480; 95% CI 0.270–0.855; p = 0.013), PLR (HR, 2.152; 95% CI 1.163–3.981; p = 0.015), and MWR (HR, 3.360; 95% CI 1.830–6.170; p < 0.001) might have a significant impact on the prognosis. Conclusion Calcium, MWR, and PLR might be related to the prognosis of MPM patients. Analyzing the relationship between the results of inflammation-related and electrolyte laboratory variables in peripheral blood and prognosis could help clinicians evaluate the situation of patients.

[1]  B. Dong,et al.  Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies , 2021, Experimental Hematology & Oncology.

[2]  J. V. van Meerbeeck,et al.  Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis , 2021, European Respiratory Review.

[3]  Letter to the Editor: Comment on 'Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions'. , 2021, Lung Cancer.

[4]  W. Richards,et al.  Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  S. Montefort,et al.  The association between pleural fluid exposure and survival in pleural mesothelioma. , 2021, Chest.

[6]  M. Johansson,et al.  Systemic inflammation markers and cancer incidence in the UK Biobank , 2021, European Journal of Epidemiology.

[7]  Y. Lacasse,et al.  Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions. , 2021, Lung cancer.

[8]  B. Ghanim,et al.  Biomarkers for Malignant Pleural Mesothelioma—A Novel View on Inflammation , 2021, Cancers.

[9]  C. Meristoudis,et al.  Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting , 2021, Acta oncologica.

[10]  D. Sugarbaker,et al.  Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma , 2020, Annals of surgery.

[11]  M. Clerici,et al.  Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. , 2020, Lung cancer.

[12]  M. Balancin,et al.  An integrative histopathologic clustering model based on immuno‐matrix elements to predict the risk of death in malignant mesothelioma , 2020, Cancer medicine.

[13]  S. Chari,et al.  Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study. , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[14]  Y. Doki,et al.  Peri-operative monocyte count is a marker of poor prognosis in gastric cancer: increased monocytes are a characteristic of myeloid-derived suppressor cells , 2019, Cancer Immunology, Immunotherapy.

[15]  S. Su,et al.  The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma , 2019, Oncology Research and Treatment.

[16]  J. Zucman‐Rossi,et al.  Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications , 2019, Nature Communications.

[17]  Huy Q. Dinh,et al.  Monocyte heterogeneity and functions in cancer , 2019, Journal of leukocyte biology.

[18]  Dongliang Yang,et al.  Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma , 2019, Gastroenterology research and practice.

[19]  Wei-min Li,et al.  High postoperative monocyte indicates inferior Clinicopathological characteristics and worse prognosis in lung adenocarcinoma or squamous cell carcinoma after lobectomy , 2018, BMC Cancer.

[20]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[21]  E. Morii,et al.  Peripheral blood monocyte count reflecting tumor‐infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens , 2017, The Prostate.

[22]  G. Thomas,et al.  Evaluating the effect of immune cells on the outcome of patients with mesothelioma , 2017, British Journal of Cancer.

[23]  J. Aerts,et al.  Novel insights into mesothelioma biology and implications for therapy , 2017, Nature Reviews Cancer.

[24]  N. Hens,et al.  Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma , 2017, Oncoimmunology.

[25]  G. Reid,et al.  KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma , 2016, Molecular Cancer.

[26]  N. Le Stang,et al.  Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. , 2016, Human pathology.

[27]  M. Zauderer,et al.  Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  Y. Maehara,et al.  Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. , 2015, Journal of thoracic disease.

[29]  N. Maskell,et al.  Individualised management of malignant pleural effusion. , 2015, The Lancet. Respiratory medicine.

[30]  N. Pavlakis,et al.  Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales , 2014, British Journal of Cancer.

[31]  J. Creaney,et al.  Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma , 2013, British Journal of Cancer.

[32]  L. Mutti,et al.  Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2—dependent T-type Ca2+ channel opening , 2012, Journal of cellular and molecular medicine.

[33]  Y. Takeshima,et al.  National survey of malignant mesothelioma and asbestos exposure in Japan , 2012, Cancer science.

[34]  R. Ramakrishnan,et al.  Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  D. Sugarbaker,et al.  Circulating and tumor‐infiltrating myeloid cells predict survival in human pleural mesothelioma , 2011, Cancer.

[36]  D. Klippenstein,et al.  Malignant pleural mesothelioma after household exposure to asbestos. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Allavena,et al.  Role of tumor-associated macrophages in tumor progression and invasion , 2006, Cancer and Metastasis Reviews.

[38]  H. Hammad,et al.  Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses , 2006, European Respiratory Journal.

[39]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[40]  D. McMillan,et al.  Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. , 2010, Future oncology.